<!DOCTYPE html><html><head><title> Pacifica Code Section 58-17b-S627 </title><link rel="stylesheet" href="/assets/style.css"/></head><body>
<b><i>
                      Effective 7/1/2022</i></b>
<br>
<b>58-17b-627.&nbsp;
          </b><b>Prescription of drugs or devices by a pharmacist.</b>
<br>
<a id="58-17b-627(1)" name="58-17b-627(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
Beginning January 1, 2022, a pharmacist may prescribe a prescription drug or device if:
<a id="58-17b-627(1)(a)" name="58-17b-627(1)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
prescribing the prescription drug or device is within the scope of the pharmacist's training and experience;</td>
</tr>
</tbody></table>
<a id="58-17b-627(1)(b)" name="58-17b-627(1)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
the prescription drug or device is designated by the division by rule under Subsection <a href="#58-17b-627(3)(a)">(3)(a)</a>; and</td>
</tr>
</tbody></table>
<a id="58-17b-627(1)(c)" name="58-17b-627(1)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
the prescription drug or device is not a controlled substance that is included in Schedules I, II, III, or IV of:<a id="58-17b-627(1)(c)(i)" name="58-17b-627(1)(c)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
Section <a href="../../Title58/Chapter37/58-37-S4.html?v=C58-37-S4_2022050420220504">58-37-4</a>; or</td>
</tr>
</tbody></table>
<a id="58-17b-627(1)(c)(ii)" name="58-17b-627(1)(c)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
the federal Controlled Substances Act, Title II, P.L. 91-513.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-17b-627(2)" name="58-17b-627(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
Nothing in this section requires a pharmacist to issue a prescription for a prescription drug or device.</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)" name="58-17b-627(3)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(3)</td><td style="width:99%">
The division shall make rules in accordance with <a href="../../Title63G/Chapter3/63G-3.html?v=C63G-3_1800010118000101">Title 63G, Chapter 3, Utah Administrative Rulemaking Act</a>, to:
<a id="58-17b-627(3)(a)" name="58-17b-627(3)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
designate the prescription drugs or devices that may be prescribed by a pharmacist under this section, beginning with prescription drugs or devices that address a public health concern that is designated by the Department of Health and Human Services, including:<a id="58-17b-627(3)(a)(i)" name="58-17b-627(3)(a)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
post-exposure HIV prophylaxis;</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)(a)(ii)" name="58-17b-627(3)(a)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
pre-exposure HIV prophylaxis;</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)(a)(iii)" name="58-17b-627(3)(a)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
self-administered hormonal contraceptives;</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)(a)(iv)" name="58-17b-627(3)(a)(iv)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iv)</td><td style="width:99%">
smoking cessation; and</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)(a)(v)" name="58-17b-627(3)(a)(v)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(v)</td><td style="width:99%">
naloxone;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)(b)" name="58-17b-627(3)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
create guidelines that a pharmacist must follow when prescribing a prescription drug or device, including guidelines:<a id="58-17b-627(3)(b)(i)" name="58-17b-627(3)(b)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
for notifying the patient's primary care or other health care provider about the prescription; and</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)(b)(ii)" name="58-17b-627(3)(b)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
to prevent the over-prescription of drugs or devices including but not limited to antibiotics;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)(c)" name="58-17b-627(3)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
address when a pharmacist should refer the patient to an appropriate health care provider or otherwise encourage the patient to seek further medical care; and</td>
</tr>
</tbody></table>
<a id="58-17b-627(3)(d)" name="58-17b-627(3)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
implement the provisions of this section.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-17b-627(4)" name="58-17b-627(4)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(4)</td><td style="width:99%">
The division shall make rules under Subsection <a href="#58-17b-627(3)">(3)</a> in collaboration with:
<a id="58-17b-627(4)(a)" name="58-17b-627(4)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
individuals representing pharmacies and pharmacists;</td>
</tr>
</tbody></table>
<a id="58-17b-627(4)(b)" name="58-17b-627(4)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
individuals representing physicians and advanced practice clinicians; and</td>
</tr>
</tbody></table>
<a id="58-17b-627(4)(c)" name="58-17b-627(4)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%"><a id="58-17b-627(4)(c)(i)" name="58-17b-627(4)(c)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
if the executive director of the Department of Health and Human Services is a physician, the executive director of the Department of Health and Human Services;</td>
</tr>
</tbody></table>
<a id="58-17b-627(4)(c)(ii)" name="58-17b-627(4)(c)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
if the executive director of the Department of Health and Human Services is not a physician, a deputy director who is a physician in accordance with Subsection <a href="../../Title26B/Chapter1/26B-1-S203.html?v=C26B-1-S203_2022050420220701#26B-1-203(4)">26B-1-203(4)</a>; or</td>
</tr>
</tbody></table>
<a id="58-17b-627(4)(c)(iii)" name="58-17b-627(4)(c)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
a designee of the individual described in Section <a href="../../Title26B/Chapter1/26B-1-S203.html?v=C26B-1-S203_2022050420220701">26B-1-203</a>.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-17b-627(5)" name="58-17b-627(5)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(5)</td><td style="width:99%">
Before November 1 of each year, the division, in consultation with the individuals described in Subsection <a href="#58-17b-627(4)">(4)</a>, shall:
<a id="58-17b-627(5)(a)" name="58-17b-627(5)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
develop recommendations for statutory changes to improve patient access to prescribed drugs in the state; and</td>
</tr>
</tbody></table>
<a id="58-17b-627(5)(b)" name="58-17b-627(5)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
report the recommendations developed under Subsection <a href="#58-17b-627(5)(a)">(5)(a)</a> to the Health and Human Services Interim Committee.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=255&amp;sess=2022GS">255</a>, 2022 General Session<br>
</body></html>